Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ICICON Public Limited Company logo

ICON Public Limited Company (ICLR)

NASDAQ · Currency in USD
$185.27 ▼ -0.16 (-0.09%)
At close: Oct 23, 4:00 PM ET. Market closed.
$185.45 ▲ +0.18 (+0.10%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$185.43
Open
$184.25
Day's Range
$179.89 – $185.57
52 Week Range
$66.57 – $203.91
Volume
1,017,948
Avg. Volume
866,208
Market Cap
$14.29B
Beta (5Y Monthly)
1.24
PE Ratio (TTM)
43.18
EPS (TTM)
$4.28
Earnings Date
Oct 27, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$173.82

Profile: ICON Public Limited Company

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
40,200
CEO
Barry Balfe

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.

Earnings

Next report: Tue, Oct 27, 2026
EPS estimate $2.62 · Revenue est. $2.01B
DateEst.Actual
Jul 29, 2026$2.55$2.56Beat
Jun 23, 2026$2.46$2.50Beat
May 27, 2026$3.13$2.52Miss
Oct 22, 2025$3.28$3.31Beat
Jul 23, 2025$3.19$3.26Beat
Apr 30, 2025$3.11$3.19Beat

Analyst view

Consensus price target
$173.82 ▼ -6.2%
Range $105.00 – $207.00
Rating: Buy
Buy 57% · Hold 37% · Sell 7%

Get free alerts on ICLR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.